Cargando…
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients
Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281137/ https://www.ncbi.nlm.nih.gov/pubmed/32366019 http://dx.doi.org/10.3390/cancers12051131 |
_version_ | 1783543852412436480 |
---|---|
author | Merz, Valeria Cavaliere, Alessandro Messina, Carlo Salati, Massimiliano Zecchetto, Camilla Casalino, Simona Milella, Michele Caffo, Orazio Melisi, Davide |
author_facet | Merz, Valeria Cavaliere, Alessandro Messina, Carlo Salati, Massimiliano Zecchetto, Camilla Casalino, Simona Milella, Michele Caffo, Orazio Melisi, Davide |
author_sort | Merz, Valeria |
collection | PubMed |
description | Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate the efficacy of oxaliplatin-based compared to irinotecan-based therapies in this setting. 181 advanced pancreatic cancer patients consecutively treated in three centers with a second-line therapy progressed on gemcitabine plus nab-paclitaxel were retrospectively enrolled. OS and PFS were calculated using the Kaplan-Meier method and survival of the two groups was compared using the log-rank test. The median PFS and OS were respectively 3.5 (95%CI 3.2–3.8) and 8.8 months (95%CI 7.9–9.8) from second-line therapy in the overall population. The median PFS and OS were respectively 3.3 (95%CI 3.1–3.5) and 8.2 months (95%CI 7.24–9.34) with an irinotecan-based combination compared to 4.0 (95%CI 2.4–5.7) and 10.3 months (95%CI 8.62–12.02) in patients receiving an oxaliplatin-based combination. We observed a clear trend for longer survival outcomes with platinum-based doublet compared to regimens including irinotecan or nal-IRI. Head-to-head trials are still lacking. The neutrophil-to-lymphocyte ratio and the presence of liver metastases could drive physicians in tailoring the treatment strategy. |
format | Online Article Text |
id | pubmed-7281137 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72811372020-06-15 Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients Merz, Valeria Cavaliere, Alessandro Messina, Carlo Salati, Massimiliano Zecchetto, Camilla Casalino, Simona Milella, Michele Caffo, Orazio Melisi, Davide Cancers (Basel) Article Pancreatic cancer is one of the most lethal solid tumors. In many European countries gemcitabine plus nab-paclitaxel is the preferred first-line treatment. An increasing number of patients are eligible for second-line therapy, but the best regimen is still controversial. This study aimed to evaluate the efficacy of oxaliplatin-based compared to irinotecan-based therapies in this setting. 181 advanced pancreatic cancer patients consecutively treated in three centers with a second-line therapy progressed on gemcitabine plus nab-paclitaxel were retrospectively enrolled. OS and PFS were calculated using the Kaplan-Meier method and survival of the two groups was compared using the log-rank test. The median PFS and OS were respectively 3.5 (95%CI 3.2–3.8) and 8.8 months (95%CI 7.9–9.8) from second-line therapy in the overall population. The median PFS and OS were respectively 3.3 (95%CI 3.1–3.5) and 8.2 months (95%CI 7.24–9.34) with an irinotecan-based combination compared to 4.0 (95%CI 2.4–5.7) and 10.3 months (95%CI 8.62–12.02) in patients receiving an oxaliplatin-based combination. We observed a clear trend for longer survival outcomes with platinum-based doublet compared to regimens including irinotecan or nal-IRI. Head-to-head trials are still lacking. The neutrophil-to-lymphocyte ratio and the presence of liver metastases could drive physicians in tailoring the treatment strategy. MDPI 2020-04-30 /pmc/articles/PMC7281137/ /pubmed/32366019 http://dx.doi.org/10.3390/cancers12051131 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Merz, Valeria Cavaliere, Alessandro Messina, Carlo Salati, Massimiliano Zecchetto, Camilla Casalino, Simona Milella, Michele Caffo, Orazio Melisi, Davide Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title_full | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title_fullStr | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title_full_unstemmed | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title_short | Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients |
title_sort | multicenter retrospective analysis of second-line therapy after gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281137/ https://www.ncbi.nlm.nih.gov/pubmed/32366019 http://dx.doi.org/10.3390/cancers12051131 |
work_keys_str_mv | AT merzvaleria multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT cavalierealessandro multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT messinacarlo multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT salatimassimiliano multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT zecchettocamilla multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT casalinosimona multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT milellamichele multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT caffoorazio multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients AT melisidavide multicenterretrospectiveanalysisofsecondlinetherapyaftergemcitabineplusnabpaclitaxelinadvancedpancreaticcancerpatients |